|
1
|
Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
|
J Clin Oncol
|
2005
|
4.27
|
|
2
|
Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
|
Blood
|
2005
|
1.81
|
|
3
|
Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.
|
Blood
|
2005
|
1.58
|
|
4
|
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
|
Blood
|
2005
|
1.32
|
|
5
|
Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit.
|
J Infect Dis
|
2011
|
1.31
|
|
6
|
Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
|
Blood
|
2002
|
1.21
|
|
7
|
Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.
|
Blood
|
2003
|
1.13
|
|
8
|
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
|
Br J Haematol
|
2012
|
1.08
|
|
9
|
Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias.
|
Am J Pathol
|
2003
|
1.05
|
|
10
|
The clinical outcome and toxicity of high-dose chemotherapy and autologous stem cell transplantation in patients with myeloma or amyloid and severe renal impairment: a British Society of Blood and Marrow Transplantation study.
|
Br J Haematol
|
2006
|
1.03
|
|
11
|
Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated.
|
J Clin Oncol
|
2005
|
0.97
|
|
12
|
SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.
|
Cancer Res
|
2010
|
0.92
|
|
13
|
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
|
Br J Haematol
|
2011
|
0.92
|
|
14
|
ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.
|
Haematologica
|
2011
|
0.91
|
|
15
|
T-cell depletion with Campath-1H "in the bag" for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival.
|
Br J Haematol
|
2003
|
0.86
|
|
16
|
Cellular uptake, distribution and cytotoxicity of the hydrophobic cell penetrating peptide sequence PFVYLI linked to the proapoptotic domain peptide PAD.
|
J Control Release
|
2009
|
0.84
|
|
17
|
South Asian chronic lymphocytic leukaemia patients have more rapid disease progression in comparison to White patients.
|
Br J Haematol
|
2008
|
0.82
|
|
18
|
Two germ line polymorphisms of the tumour suppressor gene p53 may influence the biology of chronic lymphocytic leukaemia.
|
Leuk Res
|
2006
|
0.82
|
|
19
|
Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38.
|
Haematologica
|
2010
|
0.80
|
|
20
|
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia.
|
Br J Haematol
|
2003
|
0.79
|
|
21
|
Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia.
|
J Proteome Res
|
2014
|
0.78
|
|
22
|
Co-operative membrane disruption between cell-penetrating peptide and cargo: implications for the therapeutic use of the Bcl-2 converter peptide D-NuBCP-9-r8.
|
Mol Ther
|
2011
|
0.77
|
|
23
|
The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers and survival in multiple myeloma.
|
Leuk Lymphoma
|
2006
|
0.76
|